1 / 32

A novel mutation in the AVPR2 gene in a Palestinian family with nephrogenic diabetes insipidus

A novel mutation in the AVPR2 gene in a Palestinian family with nephrogenic diabetes insipidus. Abdulsalam Abu Libdeh, MD Pediatric Endocrinologist Makassed Islamic Hospital. Case presentation.

ryu
Download Presentation

A novel mutation in the AVPR2 gene in a Palestinian family with nephrogenic diabetes insipidus

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A novel mutation in the AVPR2 gene in a Palestinian family with nephrogenic diabetes insipidus Abdulsalam Abu Libdeh, MD Pediatric Endocrinologist Makassed Islamic Hospital

  2. Case presentation • 3 months old male infant, referred from Al-Watani hospital c/o fever, irritability, FTT and vomiting. • Past history: product of FT,NVD, birth wt: 3.6kg, at Rafidia hospital. At 22d of age admitted to Al-Watani hospital as he developed fever, irritability, vomiting and FTT.

  3. Case presentation • Investigations at al-Watani: Na :177 K: 4.5 Urea: 44 Crea: 0.9 LFT: NL CBC: NL Urinalysis : free • Family history: Parents were healthy and not consanguineous. A male sibling was diagnosed clinically previously to have nephrogenic diabetes insipidus. • He was started on hydrochlorothiazide 2mg/kg/day, but due to inadequate response, the patient was referred to Makassed hospital.

  4. Case presentation • Physical Examination: Wt: 4.42kg <3rd% Lt: 58cm 25th% Hc: 37.5cm <3rd% Temp: 37c HR: 130/min BP: 72/45 Positive findings on P/E Cachectic , irritable

  5. Case presentation • Investigations: Na+: 150 K+: 3.7 s.osmolality: 304mOsm/kg BUN: 13 Crea: 0.5 LFT: NL Glu: 97 CBC: NL Blood gas: PH 7.52, HCO3 29, BE +6 Urine: osmolality: 145mOsm/kg Na: 27

  6. Family pedigree ● ●

  7. Case presentation • Investigations: Urine output: 9cc/kg/hr Urine culture: positive for Klebsiella Blood culture: negative Renal U/S : normal GFR: 43ml/min/1.73m2

  8. Diagnosis Diabetes Insipidus Central Nephrogenic

  9. Management • Minirin test: • Diagnosis: Nephrogenic Diabetes Insipidus

  10. Management • Kaluril (Amiloride & hydrochlorothiazide) 4mg/kg/day • Indomethacin 2mg/kg/day • Feeding 180cc/kg/day (oral & gavage) • Upon discharge: Na: 139 s.osm: 323mOsm/kg urine osm: 85mOsm/kg U.O.P: 2.4cc/kg/hr Wt: 5.1kg

  11. Molecular diagnosis

  12. Sequencing of AVPR2 • Primers for amplification and sequencing of the AVPR2 gene were: • Exon 1: For: attgaacttgctcctcaggc Rev.: gcttccctgaatcgtcaaac • Exon 2-start: For: ctaggagccaggaagtggg Rev.: gaagatgaagagctggggc • Exon 2-end: For: tcctcctacatgatcctggc Rev.: tggaggatctaggttgggttc • Exon 3: For: gtggctagggctgacgg Rev.: ccagtggctcccaggac

  13. Sequence result Patient Sequencing the DNA of the affected patient showed mis-sense mutation with replacement of G by A in codon 82 (TGC---TAC). This mutation predicted a substitution of Cysteine to Tyrosine (C82Y) at the amino acid residue of the AVPR2 gene

  14. Sequence result Mother Mother was heterozygous for this mutation (carrier)

  15. Sequence result Father

  16. Sequence result Sister Sister was heterozygous for this mutation (carrier)

  17. AVPR2

  18. 3-D Model of the AVPR2

  19. Nephrogenic Diabetes Insipidus • Definition: NDI is a clinical disorder, characterized by a urinary concentrating defect resulting from resistance of the collecting duct to the antidiuretic action of vasopressin (AVP).

  20. Nephrogenic Diabetes Insipidus • Classification: Hereditary X-linked V2R Autosomal recessive AQP2 Autosomal dominant AQP2 Acquired Drugs (lithium, amphotericin B) Ureteral obstruction Acute or chronic renal failure Renal cystic disease Interstitial nephritis Nephrocalcinosis Toxic nephropathy due to hypokalemia

  21. X-linked Nephrogenic Diabetes Insipidus • X-linked recessive NDI is caused by mutations in the gene encoding the V2 vasopressin receptor (V2R) and is the most frequent genetic cause of the inherited NDI. • To date, 178 different mutations have been reported for V2R NDI, and the mutations spread throughout all portions of the protein.

  22. X-linked NDI • There are two different receptors for ADH: V1 (AVPR1) & V2 (AVPR2) receptors. • Activation of the V1 receptors:- a. Induces vasoconstriction b. Enhancement of prostaglandin release, while • Activation of V2 receptors:- a. Mediate the antidiuretic responses. b. Peripheral vasodilation c. The release of factor VIIIc and von Willbrand’s factor from endothelial cells.

  23. X-linked NDI Pathogenesis

  24. X-linked NDI • Clinical manifestations: Massive polyuria Volume depletion Hypernatremia Hyperthermia Irritability Constipation FTT Developmental delay & mental retardation

  25. X-linked NDI • Clinical manifestations: Diminished appetite & poor food intake due to consumption of large volume of water Growth abnormalities. Behavioral problems, including hyperactivity & short term memory problems.

  26. Nephrogenic Diabetes Insipidus • Diagnosis:water deprivation test If the serum osmolality is 290mOsm/kg or higher with a urine osmolality value <290mOsm/kg, water deprivation test is not necessary. To distinguish between central DI & NDI: administration of vasopressin 10-20mcg, followed by serial urine and serum osmolality measurements hourly for 4hrs.

  27. Treatment of NDI • Maintenance of adequate fluid intake & access to free water. Infants require gastrostomy or NG tube feeding to ensure adequate fluid administration throughout day & night. • Minimizing urine output by limiting solute load with a low osmolar, low-sodium diet. For infants, human milk or a low solute formula, such as Similac PM 60/40 is preferred.

  28. Treatment of NDI • Administering medications directed at decreasing urine output. Thiazide diuretics (2-3mg/kg/d) effectively induce Na loss & stimulate proximal tubule reabsorption of water. Potassium-sparing diuretics, amiloride (0.3mg/kg/d) by its additive effect with thiazide are often indicated.

  29. Treatment of NDI • NSAIDs – indomethacin (2mg/kg/d) has an additive effect in reducing water excretion in some patients, dependent upon inhibition of renal prostaglandin synthesis. • Exogenous ADH: most patients with NDI have partial rather than complete resistance to ADH. It is therefore possible that attaining supraphysiologic hormone levels will increase the renal effect of ADH to a clinically important degree.

  30. Treatment of NDI • Experimental approaches: most patients with congenital x-linked NDI have defective V2 vasopressin receptors that are unable to properly fold intracellularly and, as a consequence, correctly transfer to the cell surface. In vitro, the administration of selective, cell permeable nonpeptide V2 and V1a receptor antagonists were able to rescue mutant V2 receptors by promoting their proper folding and maturation. This resulted in the expression of functional cell surface V2 receptors, suggesting that such a therapeutic approach may be fruitful.

  31. A novel mutation in the AVPR2 gene in a Palestinian family with nephrogenic diabetes insipidus Abu Libdeh Abdulsalam, Dweikat Imad & Abu-Libdeh Bassam Department of Pediatrics, Makassed Hospital, Jerusalem

  32. Thank you for your attention

More Related